Streetbeat News

Stock Prices

MDWD

MediWound Ltd. (NASDAQ:MDWD) announced positive results from the NEXT Protocol for NexoBrid in burn treatment, showing high efficacy and safety. The study reaffirmed NexoBrid's benefits in managing severe burns, reducing the need for surgical interventions, and enhancing patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:36 am

IXHL

Incannex Healthcare Inc. (NASDAQ: IXHL) has received FDA approval to conduct a Phase 2 clinical trial for its psilocybin pharmaceutical formulation, PSX-001, in patients with generalized anxiety disorder in the US and UK. The trial, PsiGAD2, will involve 94 patients and aims to measure changes in anxiety levels using the HAM-A score.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:34 am

TSN

Tyson shares are trading higher following better-than-expected Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:31 am

TSN

Tyson Foods (NYSE:TSN) reported Q3 2024 adjusted EPS of $0.87, beating the estimate of $0.65 by 33.85%. Sales were $13.353 billion, surpassing the $13.236 billion estimate and showing a 1.62% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

ALZN

Alzamend Neuro aims to compare lithium levels in the human brain to identify an ideal dose of AL001 that is both safe and effective, potentially improving current products.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

ALZN

Alzamend Neuro Inc. (NASDAQ:ALZN) is conducting a Phase 2 clinical trial of its Alzheimer's candidate AL001 in partnership with Massachusetts General Hospital. The trial aims to compare AL001's effectiveness and safety against a commonly marketed lithium salt. The study will help meet FDA regulatory safety standards and could lead to a next-generation lithium product with an improved safety profile. Alzamend previously completed a Phase 2A trial identifying a maximum tolerated dose for AL001. The company also terminated its 'at-the-market' equity offering program to preserve shareholder value.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 11:30 am

ALZN

Alzamend Neuro announced a head-to-head study of its AL001 product versus a marketed lithium carbonate product.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

ALZN

Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II trial of AL001, targeting Alzheimer's disease patients.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

DIS

IMAX

SPY

VOO

Walt Disney Co (NYSE:DIS) and Marvel Studios' 'Deadpool & Wolverine' grossed $824 million globally after two weekends, contributing to Disney surpassing $3 billion in worldwide ticket sales in 2024. The film has also performed well in premium formats like Imax Corp (NYSE:IMAX). Disney's stock closed lower by 3.74%, while IMAX closed higher by 0.57%.

Portfolio Pulse from Anusuya Lahiri

August 05, 2024 | 11:29 am

GOOG

GOOGL

META

MSFT

NVDA

NVDL

SMH

SOXL

SOXX

USD

Chip stocks-linked ETFs, including SOXL, NVDL, USD, SMH, and SOXX, experienced significant declines in pre-market trading amid a global market downturn. The drop is attributed to recession fears sparked by a disappointing U.S. jobs report and Nvidia's production delays.

Portfolio Pulse from Benzinga Neuro

August 05, 2024 | 11:27 am